Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 5, 2017, Pages 525.e1-525.e12

  Saccone, Gabriele ^a,b   Berghella, Vincenzo ^c   Maruotti, Giuseppe Maria ^a,b   Ghi, Tullio ^b,d   Rizzo, Giuseppe ^b,e   Simonazzi, Giuliana ^f   Rizzo, Nicola ^f   Facchinetti, Fabio ^g   Dall'Asta, Andrea ^d   Visentin, Silvia ^b,h   Sarno, Laura ^a,b   Xodo, Serena ⁱ   Bernabini, Dalila ^f   Monari, Francesca ^g   Roman, Amanda ^c   Eke, Ahizechukwu Chigoziem ^j   Hoxha, Ariela ^h   Ruffatti, Amelia ^h   Schuit, Ewoud ^k   Martinelli, Pasquale ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Italian Society of Ultrasound in Obstetrics and Gynecology (SIEOG)   (Italy)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

antiphospholipid antibody; autoimmune disorder; preeclampsia; preterm birth; thrombophilia

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DALTEPARIN; ENOXAPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA2 GLYCOPROTEIN 1; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COUNSELING; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; FETAL GROWTH RETARDATION; IMMUNOLOGY; ITALY; LIVE BIRTH; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; STILLBIRTH;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BETA 2-GLYCOPROTEIN I; COHORT STUDIES; FEMALE; FETAL GROWTH RETARDATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; ITALY; LIVE BIRTH; PLATELET AGGREGATION INHIBITORS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; STILLBIRTH;

EID: 85015780849     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2017.01.026     Document Type: Conference Paper

References (27)

1. 1 Levine, J.S., Branch, D.W., Rauch, J., The antiphospholipid syndrome. N Engl J Med 346 (2002), 752–763.
2. 2 Miyakis, S., Lockshin, M.D., Atsumi, T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
3. 3 American College of Obstetricians and Gynecologists Committee on Practice Bulletins Obstetrics. Practice Bulletin No. 132: antiphospholipid syndrome. Obstet Gynecol 120 (2012), 1514–1521.
4. 4 Harris, E.N., Special report: the Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 94 (1990), 476–484.
5. 5 Pengo, V., Tripodi, A., Reber, G., et al. Update of the guidelines for lupus anticoagulant detection: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7 (2009), 1737–1740.
6. 6 American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 122 (2013), 1122–1131.
7. 7 Lees, C.C., Marlow, N., van Wassenaer-Leemhuis, A., et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet 385 (2015), 2162–2172.
8. 8 Smith, A.H., Bates, M.N., Confidence limit analyses should replace power calculation in the interpretation of epidemiologic studies. Epidemiology 3 (1992), 449–452.
9. 9 McNamee, R., Regression modelling and other methods to control confounding. Occup Environ Med 62 (2005), 500–506.
10. 10 Von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke JP for the STROBE Initiative. The strengthening the reporting of the observational studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
11. 11 Yelnik, C.M., Porter, T.F., Branch, D.W., et al. Brief report: changes in antiphospholipid antibody titers during pregnancy: data from the PROMISSE study. Arthritis Rheumatol 68 (2016), 1964–1969.
12. 12 Wilson, W.A., Gharavi, A.E., Koike, T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42 (1999), 1309–1311.
13. 13 Robertson, L., Wu, O., Langhorne, P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006), 171–196.
14. 14 do Prado, A.D., Piovesan, D.M., Staub, H.L., Horta, B.L., Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet Gynecol 116 (2010), 1433–1443.
15. 15 Chighizola, C.B., Ubiali, T., Meroni, P.L., Treatment of thrombotic antiphospholipid syndrome: the rationale of current management: an insight into future approaches. J Immunol Res 2015 (2015), 9514–9524.
16. 16 Liu, X.L., Xiao, J., Zhu, F., Anti-β2 glycoprotein I antibodies and pregnancy outcome in antiphospholipid syndrome. Acta Obstet Gynecol Scand 92 (2013), 234–237.
17. 17 Kim, M.Y., Buyon, J.P., Guerra, M.M., et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 214 (2016), 108.e1–108.e14.
18. 18 Alijotas-Reig, J., Ferrer-Oliveras, R., Ruffatti, A., et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 14 (2015), 387–395.
19. 19 Empson, M., Lassere, M., Craig, J.C., Scott, J.R., Recurrent pregnancy loss with antiphospholipid antibody: a systematic review of therapeutic trials. Obstet Gynecol 99 (2002), 135–144.
20. 20 Carreras, L.D., Perez, G.N., Vega, H.R., Casavilla, F., Lupus anticoagulant and recurrent fetal loss: successful treatment with gamma globulin. Lancet 2 (1988), 393–394.
21. 21 Scott, J.R., Branch, D.W., Kochenour, N.K., Ward, K., Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 159 (1988), 1055–1056.
22. 22 Spinnato, J.A., Clark, A.L., Pierangeli, S.S., Harris, E.N., Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 172 (1995), 690–694.
23. 23 Clark, S.L., Porter, T.F., West, F.G., Coumarin derivatives and breast-feeding. Obstet Gynecol 95 (2000), 938–940.
24. 24 Marzusch, K., Dietl, J., Klein, R., Hornung, D., Neuer, A., Berg, P.A., Recurrent first trimester spontaneous abortion associated with antiphospholipid antibodies: a pilot study of treatment with intravenous immunoglobulin. Acta Obstet Gynecol Scand 75 (1996), 922–926.
25. 25 Branch, D.W., Peaceman, A.M., Druzin, M., et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy: the Pregnancy Loss Study group. Am J Obstet Gynecol 182 (2000), 122–127.
26. 26 Harris, E.N., Pierangeli, S.S., Utilization of intravenous immunoglobulin therapy to treat recurrent pregnancy loss in the antiphospholipid syndrome: a review. Scand J Rheumatol Suppl 107 (1998), 97–102.
27. 27 Blackhouse, G., Gaebel, K., Xie, F., et al. Cost-utility of intravenous immunoglobulin (IVIG) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff Resour Alloc, 8, 2010, 14.